Skip To Content

Study ID: Novartis TOBI Podhaler CTBM100C2407

Title:

A prospective observational study in cystic fibrosis patients with chronic respiratory Pseudomonas aeruginosa infection treated with TOBI Podhaler or other FDA approved inhaled antipseudomonal antibacterial drugs

Location:
Sioux Falls Region
Principal Investigator:
James Wallace, MD
Disease:
Lung
Stage:
Unknown
Status:
Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.